References
- Kineret [Prescribing Information]. Stockholm, Sweden: Biovitrum AB; 2016.
- McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):1242-1248.
- Schiff MH, DiVittorio G, Tesser J, et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum. 2004;50(6):1752- 1760.
- Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol. 2011;41(5):1203-1217.
- Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-652.
- Vela P. Extra-articular manifestations of rheumatoid arthritis, now. EMJ Rheumatol. 2014;1:103-112.
- Sayah A, English JC. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol. 2005; 53:191-209.
- Rawlings CR, Fremlin GA, Nash J, Harding K. A rheumatology perspective on cutaneous vasculitis: assessment and investigation for the non-rheumatologist. Int Wound J. 2016; 13:17-21.